Emmaus Medical, Inc.

20725 S. WESTERN AVE., SUITE 136
Torrance, CA 90501 USA
Click for website

Research Sector Specialty Pharma

Summary Description Emmaus Medical is currently engaged in a Phase III clinical trial of of L-glutamine as a treatment for Sickle Cell Disease and has entered into a collaborative agreement for the research, development and commercialization of regenerative medicine products.

Management Yutaka Niihara, MD, MPH, CEO, President and Director Henry A. McKinnell, Jr., PhD, Chairman Peter Ludlum, Executive Vice President and Chief Financial Officer Willis C. Lee, MS, Chief Operating Officer and Director Lan T. Tran, MPH, Chief Administrative Officer and Corporate Secretary Yasushi Nagasaki, Senior Vice President, Finance Tracey C. Doi, Director Maurice J. DeWald , Director

Click here for Financial Data
Keywords: sickle cell, short bowel syndrome


Updated: Apr. 06, 2016


Founded in 2000, Emmaus Medical, Inc. is a specialty pharmaceutical company, and subsidiary of Emmaus Life Sciences, Inc., dedicated to the discovery, development and commercialization of innovative a......view more

Products / Services

We develop and commercialize treatments and therapies for rare diseases and are primarily focused on the late-stage developmentcurrently in Phase III clinical trials with the FDA of the amino a......view more

Technology / Differentiation

NutreStore [L-glutamine powder for oral solution] is indicated for the treatment of Short Bowel Syndrome (SBS) in patients receiving specialized nutritional support when used in conjunction with a re...view more


Over time, we plan to expand our business to include developing and marketing products to treat more common diseases. The primary focus of our business is the late-stage development of the amino acid ...view more


In 2011 Emmaus Medical signed a research agreement with Tokyo-based CellSeed, Inc. The companies are working jointly to develop and commercialize regenerative corneal epithelial sheets in the United S...view more